• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000078.SZ
Share

Shenzhen Neptunus Bioengineering Co., Ltd. Stocks

CN¥ 1.59Last Updated 27.07.2026

Issuer Rating

3/7
Performance

Poor

Risk

Limited

Recommendation

Sell

Market Cap

CN¥ 594.50M

CN¥ 1.59
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shenzhen Neptunus Bioengineering Co., Ltd. is a pharmaceutical enterprise primarily active in China, focusing on the research, development, production, and sale of various medicinal products. Its offerings span therapeutic categories such as anti-cancer treatments, cardiovascular and cerebrovascular medications, and pharmaceuticals derived from marine sources. Founded in 1989, the company is headquartered in Shenzhen, China.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA, overp

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 09:00

Rivian is benefiting from the growth of robotaxis. One analyst expects the stock to rise 26%.

28.07.2026 08:00

Germany will cut spending on ammunition. Which company will be negatively affected by this?

28.07.2026 07:30

An investor featured in *The Big Short* has reduced his stake in Google. He does not rule out a market correction.

28.07.2026 07:00

Hedge funds have increased their exposure to healthcare stocks to a nearly five-year high

28.07.2026 03:05

Amazon plans to deploy 5,000 satellites into orbit to compete with Starlink

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026